Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 11/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167801 | 0.89 | RIPK1 (0.43) | EPHX2NR1H4RIPK1DPP4KDM4E | |
| SCHEMBL15169811 | 0.88 | RIPK1 (0.42) | EPHX2NR1H4PTGESRIPK1DPP4 | |
| SCHEMBL1671356 | 0.88 | EPHX2 (0.38) | EPHX2NR1H4PTGESRIPK1DPP4 | |
| SCHEMBL15540907 | 0.88 | CA1 (0.39) | EPHX2NR1H4PTGESRIPK1HDAC6 | |
| SCHEMBL1671935 | 0.86 | RIPK1 (0.43) | EPHX2NR1H4PTGESRIPK1HDAC6 | |
| SCHEMBL1671164 | 0.86 | EPHX2 (0.42) | EPHX2NR1H4PTGESHDAC6CA1 | |
| SCHEMBL1671101 | 0.84 | EPHX2 (0.41) | EPHX2NR1H4PTGESHDAC6CA1 | |
| SCHEMBL1671421 | 0.83 | SMN1; SMN2 (0.38) | PTGESRIPK1CA1CA2CA7 | |
| SCHEMBL15170275 | 0.83 | IDO1 (0.41) | EPHX2NR1H4PTGESHDAC6CA1 | |
| SCHEMBL15541246 | 0.82 | PTGES (0.36) | PTGESRIPK1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2018-07-19 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| US-9949955-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-04-24 | — | — | US | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072825-A1 | PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013038308-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013038308-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-03-21 | — | — | WO | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282548-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | EPHX2 393/4885NR1H4 1100/4885PTGES 1/4885 |
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | EPHX2 127/4885NR1H4 248/4885PTGES 1/4885 |
| US-10391083-B2 | Triazolone compounds as MPGES-1 inhibitors | PTGES, PTGS1, PTGIS | EPHX2 393/4885NR1H4 1100/4885PTGES 1/4885 |
| US-20180200229-A1 | TRIAZOLONE COMPOUNDS AS MPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | EPHX2 393/4885NR1H4 1100/4885PTGES 1/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | EPHX2 393/4885NR1H4 1100/4885PTGES 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.